 reuters    dr  scott gottlieb  president donald trump s nominee to lead the u s  food and drug administration  has outlined measures he would take to untangle his ties to the pharmaceutical industry if confirmed by the senate  in an ethics disclosure form filed with the department of health and human services on tuesday  gottlieb said he would resign from multiple corporate boards including glaxosmithkline plc and consulting positions  gottlieb s financial ties to the healthcare industry are extensive  if confirmed he has agreed to recuse himself from matters in which he has a financial interest and divest his holdings in about  mostly small healthcare companies  gottlieb    is widely expected to be confirmed  though his pharmaceutical ties are likely to be scrutinized by democrats  for the past decade he has been a partner at new enterprise associates  a large venture capital fund with investments in the life sciences  he would also resign from his position at the investment firm t r  winston   co  and said he would not perform any consulting work while running the agency or participate in any matter involving previous clients for a year after last providing services to a client  gottlieb  a resident fellow at the conservative american enterprise institute think tank  is viewed favorably by the drug industry  he would be responsible for implementing key elements in the recently passed  century cures act  which calls on the agency to streamline the drug approval process  